BioSpace News Archive

F-star Therapeutics, Inc. today announced that the company will participate in two virtual investor conference events next week. Details are as follows: Ladenburg Thalmann Healthcare Conference 2021

MediWound Ltd. today announced that a peer-reviewed publication, detailing the results of a phase 2 randomized control trial of its wound debriding product candidate EscharEx®, has been published in the Wound Repair and Regeneration Journal. An interim assessment of EscharEx’s U.S. phase 2 adaptive design study for the treatment of venous leg ulcers (VLUs) is expected by end of July 2021.

Surrozen Inc. announced today that new data from its inflammatory bowel disease (IBD) program, including preclinical studies of SZN-1326 showing superior activity compared to therapeutics currently used in treatment, were presented during the 16 th Congress of the European Crohn’s and Colitis Organisation.

Tempest Therapeutics, Inc. today announced that Sam Whiting, M.D., Ph.D., chief medical officer, will participate in a webcast panel titled “Developing Therapies for the Next Immuno-Oncology Targets” at the William Blair 2021 Biotech Focus Conference on Wednesday, July 14, 2021.

Science Applications International Corp. (NYSE: SAIC ) today announced the appointment of two new senior vice presidents of Human Resources (HR) and a new corporate controller.

NLS Pharmaceutics Ltd. announces that Alex Zwyer, Chief Executive Officer and Co-Founder, is scheduled to present a corporate overview at the First Annual Access to Giving Virtual Investor Conference on July 13-15, 2021.

VistaGen Therapeutics today announced that management will participate in the ‘Updates in Neuropsych’ panel at the virtual William Blair Biotech Focus Conference 2021 on July 15, 2021 at 9:00 a.m.

Eurofins (Paris:ERF), through its empowerDX subsidiary, and Rite Aid announce the launch of an over-the-counter, FDA-authorised[1], at-home COVID-19 PCR Test Kit.

RhoVac AB (“RhoVac”), a Swedish cancer immunotherapy company, announces today on July 9th 2021, that its Safety Monitoring Committee has conducted a planned interim safety review of its clinical phase IIb trial in prostate cancer, known as BRaVac.

St. Jude Children’s Research Hospital scientists and collaborators in Sweden and Japan are reporting that the enzyme NUDT15 plays a role in how patients respond to antiviral therapy with the common drugs ganciclovir and acyclovir.